B · Normal
September 21st, Novo Nordisk stated that it plans to expand its production capacity to serve 10 times the number of obese patients using oral GLP-1 by 2030.
Related telegraphs
[Jiangsu: From January to August, the added value of industries above designated
09-22 11:22
[Novo Nordisk: Create a new business segment called blood and endocrine diseases
09-21 16:23
September 21st, Novo Nordisk aims to have sales of product lines under developme
09-21 16:06
[Pharmaceutical sector’s rally expands Huaren Pharmaceutical and more than a doz
09-21 10:43
On September 18th, Anthropic established a biological laboratory for artificial
09-18 18:19
[Zhejiang: Strive to achieve operating revenue of biopharmaceutical industry clu
09-18 17:31
Comments